Intervention: Ibuzatrelvir

Pfizer C5091010

Belgium
|
2024-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Ibuzatrelvir

Pfizer C5091018

Argentina Belgium Brazil Denmark France Germany Greece Japan Mexico Netherlands Puerto Rico Slovakia South Korea Spain Sweden Taiwan Türkiye United States of America
|
2025-2028
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Immunocompromised patients
  • Hospital
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Remdesivir
  • Ibuzatrelvir

Pfizer C5091017

Argentina Belgium Brazil Bulgaria Canada China Czechia Denmark Finland Germany Japan Mexico Slovakia South Africa South Korea Spain Taiwan Türkiye United States of America
|
2024-2028
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Adolescents (12-17 years)
  • Outpatient clinic
  • Primary care
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Ibuzatrelvir